Nephros, Inc. reported its fourth‑quarter and full‑year 2025 financial results, posting a net revenue of $4.7 million for the quarter—an increase of 22% year‑over‑year from $3.9 million in Q4 2024—and a net income of $0.1 million, which translates to earnings per share of $0.01. The company beat consensus revenue estimates of $4.11 million to $4.54 million and surpassed the consensus EPS estimate of –$0.01 by $0.02.
Full‑year 2025 revenue reached $18.8 million, up 33% from $14.2 million in 2024, while full‑year net income rose to $1.2 million from $0.1 million the previous year. The quarter’s gross margin of 58% fell from 64% in the same period last year, largely due to a 15% tariff on Italian imports that was reduced to 10% in February 2026, but the company’s cost of goods sold still increased 32% year‑over‑year and SG&A expenses grew 17% for the year and 24% in Q4.
The EPS beat of $0.01 over the –$0.01 consensus was driven by disciplined cost control and a strong mix of programmatic revenue, which grew from higher reorder activity and the addition of several new active sites. Management highlighted that the expansion of the service offering—led by Director of Service Alfred Vargas—has reduced barriers to adoption and increased recurring revenue opportunities.
Gross margin compression was offset by a robust cash position: cash and cash equivalents stood at $5.4 million at year‑end, up from $3.8 million in 2024, giving the micro‑cap a healthy runway to fund future expansion without raising additional capital.
The company did not issue formal guidance for 2026, but analyst estimates project Q1 2026 revenue of approximately $5.24 million and EPS of $0.04, with full‑year 2026 revenue expected at $21.2 million and EPS at $0.15.
Segment performance was highlighted by continued growth in the programmatic revenue stream, driven by higher reorder rates and new active sites. The launch of the PFAS 19‑Series filter and planned expansion into municipal and dental segments were also noted as key growth drivers.
Management emphasized the company’s disciplined strategy: "2025 was transformational for Nephros. We delivered 33% revenue growth following a record year in 2024 and we achieved the highest revenue in a quarter in our history. This performance reflects execution of a clear, disciplined strategy built around three growth pillars: Products, Service, and Education." CEO Robert Banks also said, "Our differentiated product portfolio remains at the center of our success. Continued expansion of reorder rates, deployment of additional sales associates, and growth beyond traditional healthcare applications drove meaningful revenue gains in 2025. Further, we extended our long‑term supply agreement with our key partner, Medica, ensuring continuity of supply and supporting sustained multi‑year growth."
The company also highlighted its new PFAS filter: "Unlike most filters that only address PFOA and PFOS, the Nephros 19‑Series PFAS Filter has been independently tested to reduce Total PFAS, offering protection against a much broader spectrum of contaminants. By combining PFAS reduction with protection against lead, asbestos, and other hazards, we believe the 19‑Series PFAS Filter helps set a new benchmark in support of safer, more reliable drinking water."
Market reaction was muted: shares fell 3.31% in after‑hours trading, but the day trade opened with a 1.83% gain before falling to a trough of –4.7%. Investors focused on margin compression and the lack of explicit guidance, which tempered enthusiasm despite the earnings beat.
The results demonstrate Nephros’ ability to maintain profitability while scaling its high‑margin filtration business. The company’s strong cash position, combined with strategic product launches and service expansion, positions it well to pursue new market opportunities, even as it navigates tariff‑related margin pressure.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.